We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Cannabinoid Technologies Holdings Plc | OCTP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.005 | -1.37% | 0.36 | 14:00:38 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.365 | 0.36 | 0.37 | 0.36 | 0.365 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/2/2024 14:05 by burtond1 Director Dealings. Raise was at .5 remember https://www.londonst |
Posted at 15/1/2024 16:01 by sep800 Over the last few months we have been seeing the share price sold into around 0.7 - 0.75p.Are we witnessing an internal share agreement or an institution on an approved funding agreement ? DGI had a deal with three 3 new directors raising £2.4M with share allocation. Are we seeing the same here ? Too many 500K 750K & 1M blocks being sold We know OCTP were looking to fund their future assets towards end Q1 2024. Maybe we may get an announcement that funding has been completed taking OCTP to production |
Posted at 04/1/2024 02:02 by sep800 We all could do with an updateFestive note on OCTP website stated little but confirmed huge advancement since last 24 months Get us back to near IPO level, We have the products |
Posted at 24/10/2023 07:15 by burtond1 A plants beauty lies in its leaves, but its strength lies in its roots."...I am excited to be buying more #OCTP personally. Given the recent Phase I results, the Company appears to me to be significantly undervalued. It is for this reason that I, along with other shareholders and employees of Kingsley, have chosen to increase our direct holding in the business..."https://to |
Posted at 20/10/2023 08:39 by burtond1 Good news this for #OCTP and a massive vote of confidence...Kingsle |
Posted at 10/10/2023 10:59 by sep800 Nice to received a positive RNS this morning as expected. Phase 2 onwards and upwards.Markets will soon wake up to OCTP |
Posted at 29/9/2023 15:06 by sep800 Very quite on here lately. Not long for confirmation of phase 1 complete. I think we have been hinted that no adverse effect therefore expecting phase 2 fairly soon. Been a long road since IPO and the share price needs some recovery. However at this level take advantage of the very low current share price Funded till next April 2024 and expect a JV or share offer to existing shareholders at a much higher level than currently. Plenty other products in the pipeline and I would expect OCTP would be a great performer during 2024.GLA |
Posted at 29/7/2023 00:05 by sep800 OCTP about to turn heads with its trials, They are still on for results Q3. Once the news confirms the drug is safe and without serious side effects it will roll on to Phase 2.This phase 1 results will surge OCTP closer to being one of those rare successful Pharmaceutical companies that their R&D actually pays dividends. @ £9M M/C will be long gone. Glad to be on board at such an early stage of success. Plenty news flow to follow. We are also seeing the price being suppress for some large buy orders, most sells are buys and with 2x 6M and 2M recent buys shows confidence. I just can't see the share price going down any further especially with recent Videos and announcements. MM's will have to let this go GLA |
Posted at 10/7/2023 16:22 by sep800 If you have researched properly what company you decide to invest in then OCTP has all the products to be fruitful. OCTP is not for day trading at this stage, nevertheless there are opportunities when the share price has fallen well below the value of a company that one should consider a time to buy or top-up. At this level it's a buy, especially with news of its phase 1 trials due. OCTP do not need to raise and still have £5M cash and are fully funded for its trials and research till 2024.All to their own, but patients will be rewarded. Buy, leave in a bottom drawer and come back next year, or trade on news GL |
Posted at 12/12/2022 07:57 by manual dexterity Oxford Cannabinoid Tech.Holdings Trading Update12/12/2022 7:00am UK Regulatory (RNS & others) Oxford Cannabinoid Techn... (LSE:OCTP) Intraday Stock Chart Monday 12 December 2022 Click Here for more Oxford Cannabinoid Techn... Charts. TIDMOCTP RNS Number : 2871J Oxford Cannabinoid Tech.Holdings 12 December 2022 Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company") Trading Update Continued progress, commencement of clinical trials of lead drug candidate imminent Financial and operational targets remain on track and on budget Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market, announces a positive trading and operational update for the six months ended 31 October 2022 ("the Period"). Financial Highlights The budget review, announced on 26 August 2022, realigned the Company's development and expenditure programme to focus on bringing the Company's lead compound, OCT461201, through Phase I clinical trials. Taking this action meant that funds, which would otherwise have been fully utilised by April 2023, are now expected to extend to Q4 2023. Importantly, the Company remains on track and on budget to commence clinical trials for OCT461201 in January 2023, with publication of its interim results for the period ended 31 October 2022 also anticipated in January 2023. During the Period, the Group incurred c.GBP3.1 million of R&D costs, with progress being made on all four programmes. As at 31 October 2022, OCTP and its subsidiary, Oxford Cannabinoid Technologies Ltd. ("OCT"), (together, "the Group") had total cash reserves of approximately GBP5 million and remained debt free. Operational update Operational progress has been consistent with the Board's expectations and the Board remains confident that OCTP will achieve the milestones set out in its current development timeline. Work under the Group's GBP2.6 million contract research agreement with Aptuit (Verona) SRL, a subsidiary of Evotec SE (together "Evotec"), which commenced in July 2021 is now almost complete. Evotec will provide the Company with a submission-ready regulatory document by the end of December 2022 and will deliver an approved batch of drug product to the OCT461201 Programme 1 Phase I clinical trial unit during Q1 2023. In addition to the progress made on OCT461201, pre-clinical work for OCT130401 is almost complete, ensuring that Programme 2 will be Phase I ready in early 2023 at which time further development will be placed on hold in order to preserve cash. Development work for Programmes 3 and 4 has also continued, with the Company still on target to be at pre-clinical stage (for programme 3) and lead stage (for programme 4) with these programmes by Q2 2023. Clarissa Sowemimo-Coker, Interim CEO of OCTP, said: " We are incredibly pleased with the ongoing progress and the fact that we remain on track to meet our financial and operational targets. This is a big achievement and is testament to the adaptability, skill, and "can do" attitude of Dr Valentino Parravicini, his team, and our external partners. "As OCTP nears a critical juncture in its journey to introduce prescription cannabinoid medicines to the US$ multi-billion pain market, we are carefully managing cash and are well placed to deliver on our key objectives. I look forward to updating the market on our continued progress with the half-year results." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company accept responsibility for the content of this announcem |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
